Ultragenyx Pharmaceutical RARE Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Collaboration And Royalty | $481.14M+17.3% | $410M+25.0% | $328M+17.4% | $279.39M+32.5% | |
| Non Cash Royalty | $111.81M+10.7% | $101M+44.3% | $70M+223% | $21.69M+20.8% | |
| Royalty | $304.22M+10.6% | $275M+50.3% | $183M+744% | $21.69M+20.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ultragenyx Pharmaceutical break its business down?
- Ultragenyx Pharmaceutical (RARE) reports revenue by product across 3 parts — Collaboration And Royalty, Non Cash Royalty and Royalty. Each is extracted from the segment footnotes and tracked over time.
- Where does Ultragenyx Pharmaceutical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ultragenyx Pharmaceutical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
